PET/CT staging of Hodgkin lymphoma in no need of routine BMB

11/14/2012 | DoctorsLounge.com

Routine bone marrow biopsy did not have a significant effect on treatment management in patients with treatment-naive Hodgkin lymphoma staged with 18F-FDG-PET/CT, according to a study in the Journal of Clinical Oncology. "The added diagnostic value from routine BMB was minimal, and positive BMB findings implied upstaging in only five patients from stage III to stage IV disease of a total of 454 included patients," researchers said.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC